GB0916335D0 - Medicaments - Google Patents

Medicaments

Info

Publication number
GB0916335D0
GB0916335D0 GBGB0916335.3A GB0916335A GB0916335D0 GB 0916335 D0 GB0916335 D0 GB 0916335D0 GB 0916335 A GB0916335 A GB 0916335A GB 0916335 D0 GB0916335 D0 GB 0916335D0
Authority
GB
United Kingdom
Prior art keywords
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0916335.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Martin W J
Original Assignee
Martin W J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin W J filed Critical Martin W J
Priority to GBGB0916335.3A priority Critical patent/GB0916335D0/en
Publication of GB0916335D0 publication Critical patent/GB0916335D0/en
Priority to PCT/GB2010/051561 priority patent/WO2011033310A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0916335.3A 2009-09-17 2009-09-17 Medicaments Ceased GB0916335D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0916335.3A GB0916335D0 (en) 2009-09-17 2009-09-17 Medicaments
PCT/GB2010/051561 WO2011033310A1 (en) 2009-09-17 2010-09-17 Encapsulated intestinal flora extracted from feces for use in the treatment of gastrointestinal disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0916335.3A GB0916335D0 (en) 2009-09-17 2009-09-17 Medicaments

Publications (1)

Publication Number Publication Date
GB0916335D0 true GB0916335D0 (en) 2009-10-28

Family

ID=41277879

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0916335.3A Ceased GB0916335D0 (en) 2009-09-17 2009-09-17 Medicaments

Country Status (2)

Country Link
GB (1) GB0916335D0 (en)
WO (1) WO2011033310A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ES2623127T3 (en) 2010-02-01 2017-07-10 Mikrobex Bacteriotherapy for Clostridium difficile colitis
BR112013002667B1 (en) 2010-08-04 2020-02-04 Thomas Julius Borody intestinal flora transplantation compositions and methods for making and using them and devices for administering them
JP2014507481A (en) 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Compositions and methods for colonic microbiota transplantation
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
LT2750682T (en) 2011-10-11 2016-10-10 Achim Biotherapeutics Ab Composition comprising anaerobically cultivated human intestinal microbiota
US9176026B2 (en) 2011-12-15 2015-11-03 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
US10130665B2 (en) 2012-05-18 2018-11-20 Genome Research Limited Method for identifying bacteria for bacteriotherapy
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP6506173B2 (en) 2012-11-23 2019-04-24 セレス セラピューティクス インコーポレイテッド Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
AU2013350328A1 (en) * 2012-11-26 2015-07-09 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
AU2014212003C1 (en) 2013-02-04 2020-07-16 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
HK1220495A1 (en) * 2013-03-14 2017-05-05 Seres Therapeutics, Inc. Methods for pathogen detection and enrichment from materials and compositions
HK1220326A1 (en) 2013-03-15 2017-05-05 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US20160129053A1 (en) * 2013-05-24 2016-05-12 President And Fellows Of Harvard College Methods of isolating microorganisms and uses thereof
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP6330032B2 (en) 2013-06-05 2018-05-23 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． Method for manufacturing, processing and packaging microbiota recovery therapy composition
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
ES3017865T3 (en) 2013-11-25 2025-05-13 Nestle Sa Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
GB201421735D0 (en) * 2014-12-07 2015-01-21 Craig Nicola M Humanized gut microbiota
SE1550189A1 (en) 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
US10793847B2 (en) 2015-05-11 2020-10-06 Mybiotics Pharma Ltd. Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut
BR112017024264B1 (en) 2015-05-14 2022-07-12 Crestovo Holdings Llc COMPOSITIONS FOR FECAL FLORA TRANSPLANTATION AND METHODS OF PREPARATION AND USE THEREOF, AND DEVICES FOR THEIR ADMINISTRATION
CN114470009A (en) 2015-05-22 2022-05-13 亚利桑那大学董事会 Methods for treating autism spectrum disorder and related symptoms
EP3939601A1 (en) 2015-06-09 2022-01-19 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
AU2017271491A1 (en) 2016-05-25 2018-12-13 Mybiotics Pharma Ltd. Composition and methods for microbiota therapy
CN109562133A (en) 2016-06-14 2019-04-02 韦丹塔生物科学股份有限公司 The treatment of clostridium difficile infection
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018140931A1 (en) * 2017-01-30 2018-08-02 The Board Of Regents Of The University Of Texas System Compositions and methods for fecal microbiota transplantation
CN110831606A (en) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 Compositions and methods for treating Parkinson's Disease (PD) and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
AU2018272048B2 (en) 2017-05-26 2024-04-04 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
AU2018318132B2 (en) 2017-08-14 2025-06-26 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
KR20200079292A (en) 2017-10-30 2020-07-02 세레스 테라퓨틱스, 인코포레이티드 Compositions and methods for treating antibiotic resistance
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
KR20210091119A (en) * 2018-08-17 2021-07-21 베단타 바이오사이언시즈, 인크. How to reduce intestinal microbiome and restore microbiome
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
JP2022541795A (en) 2019-07-19 2022-09-27 フィンチ セラピューティクス ホールディングス エルエルシー Methods and products for the treatment of gastrointestinal disorders
KR20220080104A (en) 2019-09-13 2022-06-14 핀치 테라퓨틱스 홀딩스 엘엘씨 Compositions and methods for treating autism spectrum disorders
AU2020366529A1 (en) 2019-10-18 2022-05-19 Finch Therapeutics Holdings Llc Compositions and methods for delivering a bacterial metabolite to a subject
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021142353A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
US20230201265A1 (en) 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
CN114686556A (en) * 2020-12-31 2022-07-01 石家庄市疾病预防控制中心（石家庄市卫生检测中心） A kind of detection method of intestinal flora
EP4643852A1 (en) 2024-04-29 2025-11-05 Mikrobiomik Healthcare Company S.L. Pharmaceutical composition comprising a processed faecal composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001335A1 (en) * 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5733568A (en) * 1993-12-03 1998-03-31 Lafor Laboratories Limited Micro-encapsulated lactobacilli for medical applications
UA59394C2 (en) * 1998-03-27 2003-09-15 Каділа Фармацевтікелс (І.Ей) Лтд. Process of preparing stable fixed dose composition of anti-infective agent with microorganisms as active ingredients
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
DK1885343T3 (en) * 2005-05-20 2012-01-16 Dow Global Technologies Llc Monitoring an Oral Drug Compliance Using Radio Frequency Identification Tags (RFID Tags)
DE102006062250A1 (en) * 2006-12-22 2008-06-26 Roland Saur-Brosch Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort
WO2009068656A1 (en) 2007-11-30 2009-06-04 Teagasc, The Agriculture And Food Development Authority Thuricin cd, an antimicrobial for specifically targeting clostridium difficile

Also Published As

Publication number Publication date
WO2011033310A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
GB0916335D0 (en) Medicaments
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
IL217969A (en) Inhaler
IL214250A0 (en) Inhaler
ZA201108257B (en) Inhaler
AU331057S (en) Inhaler
EP2462514A4 (en) Greenbooks
IL216700A0 (en) Inhaler
DK2464943T3 (en) Systemintegration
GB0915319D0 (en) Combination medicament
GB0914738D0 (en) Inhalers
GB0916332D0 (en) Medicaments
GB0922519D0 (en) Inhaler
EP2510125A4 (en) Hyperprimers
GB0901902D0 (en) Medicament
GB0903318D0 (en) Medicament
AU4925P (en) Bonscawi Scaevola aemula
AU4926P (en) Bonscalib Scaevola aemula
AU4924P (en) Bonscablue Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
GB0910772D0 (en) Pharmaceutical
GB201019774D0 (en) Medicaments
GB0903360D0 (en) Concept seven
GB0903335D0 (en) Concept three

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)